Evidence map›Paper›PMID 34096570›Full record

ArticleBioscience reports2021

MiR-27a-3p enhances the cisplatin sensitivity in hepatocellular carcinoma cells through inhibiting PI3K/Akt pathway.

Ying Yang, Zhifang Yang, Ruili Zhang, Chunli Jia, Rui Mao, Shaya Mahati, Yuefen Zhang, Ge Wu, Yan Na Sun, Xiao Yan Jia and 3 more

Open access · goldAbstract read
In one paragraph

Article in Bioscience reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Molecular mechanism ofTranslational cancer research · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Ying YangDepartment of Cancer Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.ORCID 0000-0002-7836-7860
Zhifang YangDepartment of Cancer Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Ruili ZhangDepartment of Cancer Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Chunli JiaDepartment of Cancer Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Rui MaoDepartment of Cancer Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Shaya MahatiDepartment of Cancer Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Yuefen ZhangDepartment of Cancer Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Ge WuDepartment of Cancer Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Yan Na SunDepartment of Cancer Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Xiao Yan JiaDepartment of Cancer Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Ainiwaer AimudulaDepartment of Cancer Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Hua ZhangDepartment of Cancer Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Yongxing BaoDepartment of Cancer Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Xinjiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) play an important role in drug resistance, and it is reported that miR-27a-3p regulated the sensitivity of cisplatin in breast cancer, lung cancer and ovarian cancer. However, the relationship between miR-27a-3p and chemosensitivity of cisplatin in hepatocellular carcinoma (HCC) was unclear, especially the underlying mechanism was unknown. In the present study, we analyzed miR-27a-3p expression levels in 372 tumor tissues and 49 adjacent tissues in HCC samples from TCGA database, and found that the miR-27a-3p was down-regulated in HCC tissues. The level of miR-27a-3p was associated with metastasis, Child-Pugh grade and race. MiR-27a-3p was regarded as a favorable prognosis indicator for HCC patients. Then, miR-27a-3p was overexpressed in HepG2 cell, and was knocked down in PLC cell. Next, we conducted a series of in vitro assays, including MTT, apoptosis and cell cycle assays to observe the biological changes. Further, inhibitor rate and apoptosis rate were detected with pre- and post-cisplatin treatment in HCC. The results showed that overexpression of miR-27a-3p repressed the cell viability, promoted apoptosis and increased the percentage of cells in G0/G1 phase. Importantly, overexpression of miR-27a-3p significantly increased the inhibitor rate and apoptosis rate with cisplatin intervention. Besides, we found that miR-27a-3p added cisplatin sensitivity potentially through regulating PI3K/Akt signaling pathway. Taken together, miR-27a-3p acted as a tumor suppressor gene in HCC cells, and it could be useful for modulating cisplatin sensitivity in chemotherapy.

Indexed as

Antineoplastic AgentsApoptosisCarcinoma, HepatocellularCell Cycle CheckpointsCell ProliferationCisplatinDatabases, GeneticFemaleGene Expression Regulation, NeoplasticHep G2 CellsHumansLiver NeoplasmsMaleMicroRNAsMiddle AgedPhosphatidylinositol 3-KinaseAntineoplastic AgentsCisplatinMicroRNAsMIRN27 microRNA, humanPhosphatidylinositol 3-KinaseProto-Oncogene Proteins c-aktCisplatinHepatocellular cancermiR-27a-3pPI3K/Akt pathwaySensitivity

Identifiers

PMID34096570
PMCPMC8661504
OpenAlexW3167167771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.